BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23384944)

  • 21. N-terminal B-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluationof the Evolution of New-Heart Failure Study (SCREEN-HF).
    McGrady M; Reid CM; Shiel L; Wolfe R; Boffa U; Liew D; Campbell DJ; Prior D; Krum H
    Eur J Heart Fail; 2013 May; 15(5):573-80. PubMed ID: 23338855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
    Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
    Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure.
    Corell P; Gustafsson F; Kistorp C; Madsen LH; Schou M; Hildebrandt P
    Int J Cardiol; 2007 May; 117(3):395-402. PubMed ID: 16919342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of benefit and early hazard of bucindolol for Class IV heart failure.
    Anderson JL; Krause-Steinrauf H; Goldman S; Clemson BS; Domanski MJ; Hager WD; Murray DR; Mann DL; Massie BM; McNamara DM; Oren R; Rogers WJ;
    J Card Fail; 2003 Aug; 9(4):266-77. PubMed ID: 13680547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin.
    Stanton E; Hansen M; Wijeysundera HC; Kupchak P; Hall C; Rouleau JL;
    Eur J Heart Fail; 2005 Jun; 7(4):557-65. PubMed ID: 15921795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative value of BNP and NT-proBNP in diagnosis of heart failure.
    Fonseca C; Sarmento PM; Minez A; Gonçalves E; Covas R; Dias AR; Pina MJ; Ceia F
    Rev Port Cardiol; 2004; 23(7-8):979-91. PubMed ID: 15478324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure.
    Adlbrecht C; Hülsmann M; Neuhold S; Strunk G; Pacher R
    J Heart Lung Transplant; 2013 May; 32(5):533-8. PubMed ID: 23453573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial).
    Masson S; Latini R; Anand IS; Barlera S; Angelici L; Vago T; Tognoni G; Cohn JN;
    J Am Coll Cardiol; 2008 Sep; 52(12):997-1003. PubMed ID: 18786480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
    Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA
    Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive impairment: a key feature of congestive heart failure in the elderly.
    Trojano L; Antonelli Incalzi R; Acanfora D; Picone C; Mecocci P; Rengo F;
    J Neurol; 2003 Dec; 250(12):1456-63. PubMed ID: 14673579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential prognostic impact of resting heart rate in older compared with younger patients with chronic heart failure--insights from TIME-CHF.
    Zurek M; Maeder MT; Rickli H; Muzzarelli S; Sanders-van Wijk S; Abbühl H; Handschin R; Jeker U; Pfisterer M; Brunner-la Rocca HP;
    J Card Fail; 2015 Apr; 21(4):347-54. PubMed ID: 25576682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
    Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure.
    Conraads VM; Beckers P; Vaes J; Martin M; Van Hoof V; De Maeyer C; Possemiers N; Wuyts FL; Vrints CJ
    Eur Heart J; 2004 Oct; 25(20):1797-805. PubMed ID: 15474694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients.
    Racek J; Králová H; Trefil L; Rajdl D; Eiselt J
    Nephron Clin Pract; 2006; 103(4):c162-72. PubMed ID: 16645318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study.
    Cleland JG; Taylor J; Freemantle N; Goode KM; Rigby AS; Tendera M
    Eur J Heart Fail; 2012 May; 14(5):487-94. PubMed ID: 22505395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
    Pitt B; Latini R; Maggioni AP; Solomon SD; Smith BA; Wright M; Prescott MF; McMurray JJ
    Eur J Heart Fail; 2011 Jul; 13(7):755-64. PubMed ID: 21467028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.
    Morello A; Lloyd-Jones DM; Chae CU; van Kimmenade RR; Chen AC; Baggish AL; O'Donoghue M; Lee-Lewandrowski E; Januzzi JL
    Am Heart J; 2007 Jan; 153(1):90-7. PubMed ID: 17174644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure.
    Bruch C; Reinecke H; Stypmann J; Rothenburger M; Schmid C; Breithardt G; Wichter T; Gradaus R
    J Heart Lung Transplant; 2006 Sep; 25(9):1135-41. PubMed ID: 16962477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.